

SciVision Biotech Inc.

Inventor Conference 2017

Dr. Chun Chang Chen Project Manager | R&D Dept

Disclaimer

This slide contains our business prospect, financial condition and sales prognosis which are derived from our existing internal/external data analysis. The actual result of operations may differ from the expressed or implied in these forwardlooking statements due to various reasons, including but not limited to price fluctuation, competition, global economic condition, exchange rate fluctuation, market demand or other risks that beyond our control. The forward-looking statement in this release reflect the current belief of SciVision at this point and SciVision undertakes no obligation to update these statements with new information or future events.


Outline

1. Company & Product Overview

2. Business Operation

SciVision Biotech Inc.






The Leading Technology of Hyaluronic Acid ~

Company Profile

- Founded on 12th November 2001
- Listed on TSE on 12th November 2013 (Code: 1786)
- Oriented as Professional in pharmaceutical grade Hyaluronic Acid production
- Located at No.6, South Sixth Rd. & No.6, South First Rd. in Kaohsiung Export Processing Zone, Taiwan
- **Factory covers an area of 19,781.85** m² (**5,984** Taiwanese ping)
- Factory facilities & equipment conforms to ISO 13485, cGMP, US FDA and PIC/s GMP standards
 - Produces 12 million syringes of medical device (including dermal filler, synovial fluid supplement and adhesion barrier) annually

Core Technology



r viscosupj ement

Invention Patent

(19)中华人民共和国国家知识产权局				
(12)	发明专利			
*		(10)授权公告号 CN 101724164 B (45)授权公告日 2011,12,14		
(21)申请号 200810172328.6	1-5.			
(22)申请日 2008.10.31	审查员	张娜		
(73)专利权人 科妍生物科技股份有限公司 地址 中国台湾高雄市				
(72)发明人 陈拓成 陈丽凤				
(74) 专利代理机构 北京律盟知识产权代理不 责任公司 11287	行限			
代理人 刘国伟				
(51) Int. Cl.				
COBJ 3/24 (2006.01)				
COBL 5/08 (2006.01) COBK 5/1515 (2006.01)				
(56)对比文件				
CN 101244290 A, 2008. 08. 20, 权利要求				
1-5.				
CN 1774272 A, 2006. 05. 17, 全文.				
CN 101153061 A, 2008. 04. 02, 全文.				
US 2007/0026070 A1, 2007. 02. 01, 权利	要求			
86-38.				
CN 101244290 A, 2008. 08. 20, 权利要求	权	利要求书 1 页 说明书 12 页		
(54) 发明名称				
交联透明质酸的制造方法				
(57) 摘要				

本发明涉及一种制造交联透明质酸的方法. 其包含在约10℃至约30℃的低温下使包含透明 质酸的溶液进行交联反应超过约48小时,本发明 的方法不需纯化步骤即可降低交联剂的含量。



(45) Date of Patent:

US 5,808,050, 9 1998, Marco-Guia (withdrawn). CS Sponstrol, V (1998, Manuscula (unmanul), Y Tokta et al., Hydrolytic degratation of Repairconic acid, Polymer Degratation and Stability, 1995, pp. 200–273, vol. 48. Hans J.C.F. Nelis et al., A Sensitive Fluorimetric Procedure for the Determination of Alipharic Epoxides under Physiological Condi-tional Conditional Conditional Conditional Conditional Con

al. Charact

(10) Patent No.: US 9,371,402 B2

Tezel, A., & Frohickson, G. H. (2008). The science of hydromia acid dermal fillers. Journal of Cosmetic and Laser Therapy. 10(1) 15:42.*

Determination of Augment: Epotasis used: reprintingent Control, tion, Analysis all likelenminy: 1981, pp. 151–157, vol. 115.
European Search Report for 00004501.3-2115, which is a surre-spending application, that elses 1852092/04/0511, and U.S. Pat. No. 4, 716, 154, EP 1818244, 135 2006-2063137, IP 093006, Englanz et al. 2016.

munic acid derivativ

Jun. 21, 2016

發明專利說明書公台	4	本
-----------	---	---

(本說明書格式、順序及粗體字,請勿任意更動,淡記號部分請勿填寫) CO8J3/54 (2000.01)

※申請案號: 97136520

※申請日期: 97.09.23 一、發明名稱:(中文/英文)

※IPC 分類: C08B-CO815/08 (2006.01)

交聯透明質酸之製造方法

METHOD FOR PRODUCING CROSS-LINKED HYALURONIC ACID

二、申請人:(共1人)

姓名或名稱:(中文/英文) 科妍生物科技股份有限公司 SCIVISION BIOTECH INC.

代表人:(中文/英文)

住居所或營業所地址:(中文/英文)

高雄市806前鎮區高雄加工出口區南六路9號 9, SOUTH 6TH RD., K.E.P.Z., TAIWAN, R.O.C.

Taiwan

(45) 発行日 平成25	年11月13日 (2013.11.13)		(24) 登録日	平成25年8月16日	(2013.8.16
(51) Int.Cl. COBB 37/08	(2008.01) FI COSB	37/08	z		
			闘求項の数	19 外国語出版	(全 20 頁)
(21)出願證号 (22)出願證 (22)出願已 (35)公開留号 (43)公開日 審査課求日 (31)優先権主張百 (33)優先権主張百	1982/2009-219164(92009-219164) 甲酸219-09742(2009-0-20) 1982/2010-77434(92010-77434) 甲酸2294-7月82(2010-4.8) 甲酸2294-7月82(2010-4.8) 甲酸2294-7月721日(2010-5.7) 0971/20520 甲酸2017/20540 甲酸2017/20540 甲酸2017/20540 甲酸2017/20540 甲酸2017/20540 甲酸2017/20540 甲酸2017/20540 甲酸2010-77550 甲酸2019/20540 甲酸2010-77550 P (2010-77550) P (2010-77	(74)代理人 (74)代理人 (72)発明者	料研生物料 台湾高域市新 100108453 弁理士 村山 100064908 弁理士 志 100089037 弁理士 環想 100110364 発理士 実近 陳拓成	正政	

(12)特許公報(B2)

(1))特許委長

特許第5340093月

最終頁に続く

(54) (発明の名称) 星橋ヒアルロン酸の製造方法

(19)日本国特許疗(JP)

(57)【特許請求の範囲】 (3) (昭和御永の地回3) 「御永道」」 アルカウ集件において、七氏10~30度の新道で、4月時間以上の反応時間をかけて 1種類又は複数種類のポリマーと架構剤とを実施能合させることにより、知識してルロン 離を形成させるスケップを有し、試ポリマーは、ヒアルロン機、ビアルロン機、ビアル ロン機とどアルコン機はとごが合称。ヒアルロン機とビアルコン機会とドのないな人体する多単能との展 合物、及びヒアルロン酸塩とヒドロキシ基を有する多糖類との混合物からなる群より選択 されるものであり、 前記低温で架橋結合を行うステップの前に、さらに、セ氏35~60度の高温で架橋結 合反応を行うステップを有し、さらに、 IG んやてリンステラノを用い、こうに、 ヒドロキン最を有する前記多範囲が、カルボキシメチルセルロース(CMC)、アルギ ン鏡塩、コンドロイチン(4 - サルフェート、コンドロイチン-6 - サルフェート、キサ ンタンガム、キトサン、ペクチン、寒天、カラギーナン、グアールガムからなる群より湯 択されるものであることを特徴とす<u>る架</u>橋ヒアルロン酸の製造方法。 【請求項2】 前記ヒアルロン酸塩がヒアルロン酸ナトリウム、ヒアルロン酸カリウム、ヒアルロン酸 亜鉛からなる群より選択されるものであることを特徴とする請求項1に記載の架橋ヒアル ロン酸の製造方法。 【請求項3】

(山水県3) 前記アルカリ条件が0、05~1、5N'であることを特徴とする請求項1に記載の架 20

Japan

(19) Suropäise Patentam Patent Office ear des breeze	ice option	(11)	EP 2 236 523 A1
(12)	EUROPEAN PATH	ENT APPLICATION	
(43) Date of publication: 06.10.2010 Bulleti	n 2010/40	(51) Int CL: C08B 37/00 ^(2006,01)	C08L 5/08 ^(2006,81)
(21) Application number:	09004561.8		
(22) Date of filing: 30.03.	2009		
	Z DE DK EE ES FI FR GB GR FLU LV MC MK MT NL NO PL	 (72) Inventors: Chen, Tor-Chern Pingtung City Pingtung (TW) Chen, Li-Su Nanzi Districht (TW))
(71) Applicant: Scivision Kaohslung Export Qianzhen D Kaohs	Processing Zone	(74) Representative: Hau Neuer Wall 50 20354 Hamburg (DE	ck Patent- und Rechtsanwälte =)
(54) Method for pro	ducing cross-linked hyalur	onic acid	
(57) A method for proc	lucing cross-linked hyaluronic		e, derivatives thereof and a mix-

acid comprising cross-linking one or more polymers at a low temperature from 10 to 30 °C for a reaction time greater than 48 hours under basic condition with a cross-linking agent to form a cross-linked hyaluronic acid, wherein the polymer is selected from the group consisting of hyture thereof. Whereby, a cross-linking agent content in a product of the method is decreased so the product does not require purification.

EU

China

(12) United States Patent Chen et al. (54) METHOD FOR PRODUCING CROSS-LINKED HYALURONIC ACID (75) Inventors: Tor-Chern Chen, Kaohsiang (TW); Li-Su Chen, Kaohsiang (TW) (73) Assignce: SCIVISION BIOTECH INC., K.E.P.Z. (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 351 days. (21) Appl. No.: 13/316.840 (22) Filed: Dec. 12, 2011 Prior Publication Data (65) US 2012/0095206 A1 Apr. 19, 2012 Related U.S. Application Data (63) Continuation-in-part of application No. 12/385,502, filed on Apr. 9, 2009, now abandoned. (51) Int. CL. C08B 37/08 (2006.01)

(52) U.S.CL C08B 37/0072 (2013.01) CPC

A61K 31/715 See application file for complete search history.

(56) References Cited

U.S. PATENT DOCUMENTS

al. Characteristics of Dyalousia acid derivative fature cross-linkedby polychyleng glycol of low water content. Journal of Medical Col-lingus of PLA. Shanghai, CN, Feb. 1, 2008, pp. 15-19, vol. 23, No. 1 and Tombhata K. et al., Proparation of cross-failed hyalaronic acid films of low water content, Biomaterials, Feb. 1, 1997, pp. 189-195 vol. 18, No. 3. vol. 18, No. 3. European Office Action for 99004561.3-2115, which is a correspond-ing European application. Chinese Office Action data data. 30, 2011 for 200810172328.6, which is a corresponding Chinese application, that cites CN 101244290, and US 2007/0020970. Unissee Office Action data data 1, 29111 for 200810172328.6, which is a corresponding Chinese application. n a corresponsing Chinese application. Singhus et al., Characteriorise of hydrarosic acid derivative films cross-listed by polyethylme glycol of low water content, Journal of Medical Colleges of PLA, Shanghui, CN, Feh 1, 2008, pp. 15-19, vol. 23, No. 1. vin, 23, 100. 1. Tomhata K. et al., Preparation of cross-linked hyaharonic acid films of low water content, Biomaterials, Feb. 1, 1997, pp. 189-195, vol 18, No. 3.

18, No. 3. Office Action issued on Oct. 23, 2012 of the corresponding JP patent application Nn. 2009;219164 cites WD 2006-051936, JP 66-233101, JP 1107-102002, and JP 1802-138346. English abstract of Office Action issued on Oct. 23, 2012 of the corresponding IP patent application No. 2009-219164. Enabled advances of Web 2006-201000 IP 40-201001 IP

United States

International Strategic Alliance



























Osteoarthritis Improvement

- Improvement of cartilage cell metabolism
- Inhibition of inflammation
- Promotion of synovial fluid biosynthesis

Product Launch



SciVision Biotech Inc. 9, South 6th Rd., K.E.P.Z., Kaohsiung, 80681, Taiwan, R.O.C http://www.scivisionbiotech.co service@scivision.com.tw

TEL:+886-7-823-2258 FAX:+886-7-823-2295



Geriatrics care-Viscosupplement



Facial Aesthetics


-Dermal Filler

HADERMIS CINE HADERMIS

DERMIS

Surgery -Absorbable Adhesion Barrier

Potential and Advantage of Our Products



Facial Aesthetics -HA Dermal Filler














Sales Territories



HYADERMIS/ FACILLE HA Dermal Filler






Features

- ✓ High safety performance
- ✓ Strong structural support
- ✓ Lasting effect
- ✓ Excellent viscosity
- ✓ High proportion of active ingredient
- ✓ Superior degradation resistance



Strong structural support



Competitor 1

Our Product

Competitor 2

Geriatrics care

- Single Injection Viscosupplement



Osteoarthritis Improvement


- Improvement of cartilage cell metabolism
- Inhibition of inflammation
- Promotion of synovial fluid biosynthesis



SciVision Biotech Inc.

 South 6th Rd., K.E.P.Z., Kachslung, 80681, Taiwan, R.O.C http://www.scivisionbiotech.com service@scivision.com.tw TEL:+886-7-823-2258 FAX:+886-7-823-2295

Viscosupplements



5 Injection type:

Inject for consecutive 5 weeks/ last for six months

3 Injection type:


Inject for consecutive 3 weeks/ last for six months

Single Injection type:

Single injection/ last for a whole year



Sales Territories



HYAJOINT Plus / HYAFELIC Uno Single Injection Viscosupplement

Features

- ✓ Single Injection
- ✓ High Security Performance
- ✓ Long Lasting Effect
- ✓ High Comfort
- ✓ Needless of Excessive Injection



JBJS America, impact factor=5.163, Top international journal in Orthopedics

462

COPTRIGHT @ 2017 BY THE JOURNAL OF BONE AND JOINT SURGERY, INCORPORATED

Comparison of Single Intra-Articular Injection of Novel Hyaluronan (HYA-JOINT Plus) with Synvisc-One for Knee Osteoarthritis

A Randomized, Controlled, Double-Blind Trial of Efficacy and Safety

Shu-Fen Sun, MD, Chien-Wei Hsu, MD, Huey-Shyan Lin, PhD, I-Hsiu Liou, MD, Yin-Han Chen, MD, and Chia-Ling Hung, MD

Investigation performed at the Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan

Background: Viscosupplementation has been widely used for the treatment of knee osteoarthritis. Because we found no well controlled trial comparing single-injection regimens of hyaluronan for knee osteoarthritis, we compared the efficacy and safety of a single intra-articular injection of a novel cross-linked hyaluronan (HYA-JOINT Plus) with a single injection of Symviso-One in patients with knee osteoarthritis.

Methods: In a prospective, randomized, controlled, double-blind trial with a 6-month follow-up, 132 patients with knee osteoarthritis (Kellgren-Lawrence grade 2 or 3) were randomized to receive 1 intra-articular injection of 3 mL of HYA-JOINT Plus (20 mg/mL) (n = 66) or 6 mL of Synvisc-One (8 mg/mL) (n = 66). The primary outcome was the change from baseline in the visual analog scale (VAS) (0 to 100 mm) pain score at 6 months. Secondary outcome measures included the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC, Likert scale), Lequesne index, timed "Up & Go" (TUG) test, single-limb stance (SLS) test, use of rescue analgesics, and patient satisfaction.

Results: A total of 121 patients were available for the intention to treat analysis at 6 months. Both groups had a significant improvement in the VAS, WOMAC, and Lequesne index scores at each follow up wisit (p < 0.001). Patients who received HYA-JOINT Plus experienced a significantly greater improvement in the VAS pain score at 1, 3, and 6 months compared with those treated with Symisc-One (adjusted mean difference: -12.0, -8.5, and -6.6; p = 0.001, 0.033, and 0.045, respectively). There were no significant between group differences in any of the secondary outcomes except the WOMAC stiffness scores at 6 months, which favored HYA-JOINT Plus treatment (p = 0.043). The TUG time did not change significantly in either group during the study (p > 0.05), but the SLS time improved significant between group differences is a output by in both the HYA-JOINT Plus and the Symisc-One group (p = 0.004) and p = 0.022, respectively). No significant between group differences were no sumption of analgesics. No serious adverse events occurred following the injections.

Conclusions: A single injection of either HYA-JOINT Plus or Synvisc-One is safe and effective for 6 months in patients with knee osteoarthritis. HYA-JOINT Plus is superior to Synvisc-One in terms of reducing the VAS pain score at 1, 3, and 6 months and the WOMAC stiffness score at 6 months, with similar safety.

Level of Evidence: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.

Peer Review: This article was reviewed by the Editor-in-Chief and one Deputy Editor, and it underwent blinded review by two or more outside experts. It was also reviewed by an expert in methodology and statistics. The Deputy Editor reviewed each revision of the article, and it underwent a final review by the Editor-in-Chief prior to publication. Final corrections and calrifications occurred during one or more exchanges between the author(s) and corpeditors.

iscosupplementation with hyaluronan is a well-established treatment option for knee osteoarthritis. The goal of viscosupplementation is to reduce pain and improve viscoelasticity of synovial fluid¹². Hyaluronan may provide biological actions, including anti-inflammatory, antinociceptive, and anabolic effects¹⁶. Moreover, it has been known to

Disclosure: The study was sponsored by SciVision Biotech Corporation, the manufacturer of HYA-JOINT Plus. One author (S.-F.S.) received funding from the SciVision Biotech Corporation. Funds were used to pay for consultancy in study planning, and realization. The funding source was not involved in patient enrollment, data collection, data analysis, or manuscript preparation. The **Disclosure of Potential Conflicts of Interest** forms are provided with the online version of the article (http://inks.lww.com/JBIS/AL47).



HYAJOINT Plus

VS



Synvisc-One

Our product performs better in pain relieving




TABLE III Comparison of VAS, WOMAC, and Lequesne Index Scores Between Groups						
	HYA-JOINT Plus*	Synvisc-One*	Adjusted Mean Difference (95% Confidence Interval)	P Value†		
VAS score (mm)						
Baseline	59.3 ± 15.8	55.7 ± 16.4		0.212		
1 mo	25.1 ± 18.4	$\textbf{35.8} \pm \textbf{22.1}$	-12.0 (-19.1, -5.0)	0.001‡		
3 mo	24.7 ± 19.0	32.9 ± 24.0	-8.5 (-16.4, -0.7)	0.033‡		
6 mo	26.0 ± 15.6	$\textbf{32.3} \pm \textbf{19.6}$	-6.6 (-13.0, -0.2)	0.045†		
P value§	<0.001‡	<0.001‡				

Our product performs better in improving serious OA symptom





TABLE IV Comparison of TUG and SLS Times Between Groups					
	HYA-JOINT Plus*	Synvisc-One*	P Value†		
TUG time (sec)					
Baseline	12.3 ± 8.7	12.6 ± 13.3	0.902		
1 mo	11.2 ± 6.1	10.4 ± 3.9	0.925		
3 mo	10.9 ± 4.3	10.4 ± 3.7	HYA-JOINT Plus superior when baseline >18.8 sec		
6 mo	11.1 ± 5.0	11.4 ± 5.6	0.145		
P valueŧ	0.078	0.23			

Surgery -Absorbable Adhesion Barrier







Trends of Anti-adhesion Product

Major ingredient Evaluated item	Rubber / silicone for medical use	PLA	Chitosan	ORC	Sodium Hyaluronate
Source	artificial synthetic	artificial synthetic	animal source	artificial	Microbial fermentation
2 nd surgery needed	Yes	No	No	No	No
Inflammatory reaction	moderate	high	moderate 🗖	low	low
Adhesiveness of product	low	moderate	moderate	moderate 🗖	high

PROTAHERE Absorbable Adhesion Barrier



Features

- ✓ High Biocompatibility
- ✓ Effective Adhesion Prevention
- ✓ Safe, Natural, Absorbable
- \checkmark Easy to apply
- ✓ Cost-Effective




Outline

1. Company & Product Overview

2. Business Operation


Revenues

2015 to Oct, 2017



Product Portfolio

2015 to Oct, 2017



Dermal filler Viscosupplement Other

Vision & Prospect

Vision



Prospect

Leading HA brand in the world

The best in global market



